B
GPCR icon

Braidwell’s Structure Therapeutics GPCR Stock Holding History

Braidwell’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-435,823
Closed -$18.7M – 80
2024
Q1 		$18.7M Buy
435,823
+155,665
+56% +$6.56M 0.6% 53
2023
Q4 		$11.4M Buy
+280,158
New +$16.1M 0.42% 54

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Braidwell's GPCR Position: Q2 2024 in Review

Braidwell sold out of Structure Therapeutics (GPCR) in Q2 2024, closing a stake of 435,823 shares — an estimated $18.7M sold.

Braidwell first reported a position in GPCR in Q4 2023 and held it in 2 quarters. The position peaked at $18.7M in Q1 2024. 166 funds tracked by Wall St. Rank hold GPCR as of Q2 2024.

  • Braidwell reported no remaining Structure Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Braidwell sold 435,823 Structure Therapeutics shares in Q2 2024, an estimated $18.7M.
  • Braidwell first reported a position in Structure Therapeutics in Q4 2023 and held it in 2 quarters.
  • Braidwell's Structure Therapeutics position peaked at $18.7M in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2024.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.